
Cytegen Corporation Profile last edited on: 4/28/2022
CAGE: 7P6C5
UEI: J1LVLP8ZZAC9
Business Identifier: Engaging the fact of mM\itochondrial dysfunctions link to aging and neurodegenerative disorders Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
4230 North Oakland Avenue Unit 154
Milwaukee, WI 53211
Milwaukee, WI 53211
(650) 473-0701 |
nfo@cytegen.com |
www.cytegen.com |
Location: Single
Congr. District: 04
County: Milwaukee
Congr. District: 04
County: Milwaukee
Public Profile
With early ties to the Medical College of Wisconsin and involving - on the team - investigators with other academic institutions, Cytegen Corporation is organized around development of discovery platform designed to increase the human healthspan by reversing age-related decline in the body. Principals of the firm have discovered chemicals that promote the elimination of defective mitochondria while promoting the creation of new, healthy mitochondria - therevy enablng doctors to use genomes, proteomics, and biochemical data to optimize cellular metabolism. Focused on the link between mitochondrial dysfunction and aging along with neurodegenerative disorders such as Parkinsons and Alzheimers, the company's therapies target age-related health decline along some other rare diseases with the objective of enabling patients to improve cellular metabolism. to prevent neurodegenerative diseases, and/or effectively to reverse age related illness. The firm describe themsleves as having identified unique pathways that impact mitochondrial fitness and demonstrated recovery of cardiovascular and neurological function via therapeutic intervention.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2020 | 1 | NIH | $252,092 | |
Project Title: Determination of Circulation Factors That Mediate the Health Benefits of Exercise in Mitochondrial Aging | ||||
2018 | 1 | NIH | $241,568 | |
Project Title: Selection and Development of a Lead Biologic for Treating Mitochondrial Disorders | ||||
2017 | 1 | NIH | $210,672 | |
Project Title: A Novel Strategy to Identify Substances that Improve Mitochnodrial Fitness |
Key People / Management
George Ugras -- Founder and President
Nuray George Ugras -- Founder
Blake Hill -- CSO
R Blake Hill
Nuray George Ugras -- Founder
Blake Hill -- CSO
R Blake Hill